Efficacy and Safety of Lisdexamfetamine Dimesylate (LDX) in Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD)

NCT00735371 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

314

Enrollment

INDUSTRY

Sponsor class

Conditions

Attention Deficit Hyperactivity Disorder (ADHD)

Interventions

DRUG: LDX 30 mg
DRUG: LDX 50 mg
DRUG: LDX 70 mg
DRUG: Placebo

Sponsor

Shire